top
Please input keywords
OK
Database
Family Website
Eucure Biopharma
Biocytogen Boston Corp.
홍보센터
Contact us
KR
CN
EN
JP
회사소개
회사소개
회사 연혁
핵심인력
기업문화
사회적 책임
인재모집
합작연구개발
파이프라인
RenMice™ HiTS Platform
기술 플랫폼
핵심연구분야
신약개발 프로세스
RenMice
동물/세포 모델
동물/세포모델
질병 모델
유전자 편집
Investor Relations
Home
News events
자료 다운로드
포스터 다운로드
홍보센터
뉴스 및 각종 자료 열람
뉴스
공지사항
웨비나
논문게재실적
자료 다운로드
포스터 다운로드
제품정보 다운로드
2023
PEGS-EU 2022:YH013, A Fully-human EGFR x MET Bispecific ADC Exhibits Outstanding Specificity and Anti-tumor Efficacy
2023
PEGS-EU 2022:1C3—A Differentiated Non-Blocking Agonist TNFR2 Antibody for Cancer Immunotherapy
2023
PEGS-EU 2022:A Novel TCR-mimic Fully Human Antibodies Discovery Platform
2022
World ADC San Diego2022丨YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy
2022
AACR 2022: Evaluating Delivery of TFR1-targeting Therapies to the CNS in a Novel Humanized TFR1 Mouse Model
2022
AACR 2022: Developing a Translational Tool for GLP-1-Based Therapeutic Agonists in Humanized GLP1R Mice
2022
AACR 2022: YH008, a PD-1-CD40 Bispecific Antibody, Inhibits Tumor Growth In Vivo Through PD-1-Dependent Activation of CD40 Signaling
2022
AACR 2022: B-hIL12A/hIL12B/hIL12RB1/hIL12RB2: A Novel Animal Model for Generation of IL12 Therapies
2022
AACR 2022: Evaluation of Therapeutic Drug Candidates Using a Novel Humanized B-hCSF1/hCSF1R
1
2
3
4
GO
naver-site-verification: naver8a6b0412e3d2d9dd38f1684b831435ac.html
